Oculis (NASDAQ:OCS) Given New $39.00 Price Target at HC Wainwright

Oculis (NASDAQ:OCS) had its price target lifted by investment analysts at HC Wainwright from $26.00 to $39.00 in a research note issued on Friday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 290.78% from the company’s current price.

OCS has been the topic of a number of other research reports. Guggenheim dropped their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Stifel Nicolaus dropped their target price on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Needham & Company LLC decreased their price target on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, June 1st. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Oculis currently has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Oculis Trading Up 0.7%

NASDAQ OCS opened at $9.98 on Friday. The firm has a market capitalization of $578.64 million, a PE ratio of -5.74 and a beta of 0.52. The business’s 50-day moving average price is $12.10 and its two-hundred day moving average price is $19.01. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis has a 12 month low of $9.65 and a 12 month high of $34.47.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. The company had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. On average, analysts expect that Oculis will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OCS. Braidwell LP bought a new stake in shares of Oculis during the second quarter worth about $11,570,000. Folketrygdfondet bought a new position in Oculis in the 4th quarter valued at about $3,651,000. Propel Bio Management LLC bought a new position in Oculis in the 4th quarter valued at about $3,452,000. NEXTBio Capital Management LP acquired a new position in Oculis during the 4th quarter valued at about $2,991,000. Finally, Simplify Asset Management Inc. acquired a new position in Oculis during the 4th quarter valued at about $1,972,000. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.